Therefore, we conclude that the pharmacological inhibition of MAPK signaling in undifferentiated thyroid cancer cells carrying a BRAF or Ras mutation induces p38 phosphorylation, which subsequently activates CREB and leads to L-GILZ transcriptional activation. The gene discussed is BRAF; the disease is thyroid cancer.